Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides
Autor: | Mallika Asar, April Franco, Mette Soendergaard |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Phage display cancer targeting pancreatic cancer lcsh:QR1-502 Antineoplastic Agents Biochemistry Article lcsh:Microbiology 03 medical and health sciences Prostate cancer 0302 clinical medicine Peptide Library Cell Line Tumor Pancreatic cancer LNCaP phage medicine Humans Molecular Biology Chemistry HEK 293 cells medicine.disease Ligand (biochemistry) Molecular biology Fold change Pancreatic Neoplasms HEK293 Cells 030104 developmental biology Cell culture 030220 oncology & carcinogenesis peptides Female phage display Cell Surface Display Techniques Protein Binding |
Zdroj: | Biomolecules, Vol 10, Iss 714, p 714 (2020) Biomolecules Volume 10 Issue 5 |
ISSN: | 2218-273X |
Popis: | Pancreatic cancer is characterized by a 5-year survival rate of 3%, in part due to inadequate detection methods. The small size of peptides offers advantages regarding molecular targeting. Thus, peptides may be used in detection of pancreatic cancer. Here, peptides that target pancreatic cancer cells were selected using phage display technology using a 15-mer fUSE5 library. Phage were pre-cleared against immortalized pancreatic cells (hTERT-HPNE), followed by selections against pancreatic cancer (Mia Paca-2) cells. Next-generation sequencing identified two peptides, MCA1 and MCA2, with a Log2 fold change (Mia Paca-2/ hTERT-HPNE) > 1.5. Modified ELISA and fluorescent microscopy showed that both peptides bound significantly higher to Mia Paca-2 cells, and not to hTERT-HPNE, embryonic kidney (HEK 293), ovarian (SKOV-3) and prostate cancer (LNCaP) cell lines. Further characterization of MCA1 and MCA2 revealed EC50 values of 16.11 µ M (95% CI [9.69, 26.31 µ M]) and 97.01 µ M (95% CI [58.64, 166.30 µ M]), respectively. Based on these results, MCA1 was selected for further studies. A competitive dose response assay demonstrated specific binding and an IC50 value of 2.15 µ M (95% CI [1.28, 3.62 µ M]). Taken together, this study suggests that MCA1 may be used as a pancreatic cancer targeting ligand for detection of the disease. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |